Mylan, Genentech Strike Deal For Herceptin Biosimilar
By Dani Kass ( March 14, 2017, 6:59 PM EDT) -- Mylan NV on Monday said it has agreed to drop its challenge of two Genentech Inc. patents related to the cancer biologic Herceptin as part of a deal that will get Mylan an exclusive license to sell its biosimilar trastuzumab across the globe....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.